Kiniksa Pharmaceuticals International (NASDAQ:KNSA), Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapies for autoinflammatory and immune-mediated diseases. The company’s portfolio includes approved and late-stage investigational products that address a range of rare and debilitating conditions. Kiniksa’s lead marketed therapy, rilonacept (Arcalyst), is approved in the United States and certain international markets for the treatment of cryopyrin-associated periodic syndromes (CAPS), a group of rare hereditary inflammatory disorders. Beyond CAPS, Kiniksa is advancing rilonacept in additional indications characterized by excess interleukin-1 activity.
In addition to its marketed product, Kiniksa maintains a robust pipeline of monoclonal antibodies and small molecules. Vixarelimab, an anti–oncostatin M receptor antibody, is in development for severe pruritic skin diseases such as prurigo nodularis, while mavrilimumab, which targets the granulocyte-macrophage colony-stimulating factor receptor, is being evaluated for conditions including giant cell arteritis and rheumatoid arthritis. These investigational therapies reflect Kiniksa’s strategic focus on leveraging its immunology expertise to address significant unmet needs in inflammatory disorders.
Founded in 2017 through a series of strategic acquisitions and licensing agreements, Kiniksa has rapidly expanded its presence in North America and Europe. The company’s operations encompass research and development facilities in the United States, along with regulatory and commercial infrastructure to support product launches in key markets. By forging partnerships with patient advocacy groups and academic centers, Kiniksa ensures that its clinical programs are informed by patient insights and the latest scientific advances.
At the helm of Kiniksa is Chief Executive Officer John H. Johnson, whose experience spans pharmaceutical development, commercial operations, and corporate leadership. Under his direction, the company has grown from a research‐focused start-up to a fully integrated biopharmaceutical enterprise. Kiniksa’s leadership team combines deep scientific expertise with commercial acumen, positioning the company to bring innovative treatments to patients suffering from inflammatory and autoimmune diseases around the world.
